‘Rope Not Dope’ Still Convince Congress On Hemp?
Executive Summary
Failing to maintain key non-intoxicating distinction for hemp could cost US market its future. FDA appointment of senior policy advisor for cannabis could change things.
You may also be interested in...
Former US FDA Heads Urge Congress: Seize Opportunity For Cosmetic, Dietary Supplement Reform
Calling Congress’s failure to include cosmetic and dietary supplement riders in recent FDA user-fee reauthorization “a profound missed opportunity,” former FDA commissioners push for movement in the lame duck Congress in December.
Heightening Focus On Hemp, Cannabis, US FDA Hires Norman Birenbaum As Public Health Advisor
Hemp industry and private attorneys glad Birenbaum, who was the chief cannabis policy advisor to governors of New York and Rhode Island, given prominent role at FDA that could spur regulatory action.
Safety Concerns Are US FDA's Answer To Question On Regulatory Pathway For Hemp’s Lawful Use
While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.